FY2024 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Research analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Sangamo Therapeutics in a report issued on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings per share of ($0.40) for the year, down from their previous estimate of ($0.23). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2024 earnings at $0.07 EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.07 EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.10 EPS, FY2027 earnings at $0.29 EPS and FY2028 earnings at $0.63 EPS.

Separately, StockNews.com assumed coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They set a “sell” rating on the stock.

Sangamo Therapeutics Price Performance

Shares of NASDAQ:SGMO opened at $2.47 on Thursday. The company has a market capitalization of $514.31 million, a PE ratio of -1.79 and a beta of 1.10. The business has a fifty day moving average price of $1.08 and a 200-day moving average price of $0.77. Sangamo Therapeutics has a 1-year low of $0.29 and a 1-year high of $2.56.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. The company had revenue of $0.36 million for the quarter, compared to the consensus estimate of $11.40 million.

Institutional Trading of Sangamo Therapeutics

A number of large investors have recently added to or reduced their stakes in SGMO. Meritage Portfolio Management grew its holdings in shares of Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 6,740 shares in the last quarter. Golden State Equity Partners increased its holdings in shares of Sangamo Therapeutics by 35.2% in the 3rd quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 69,368 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 38,850 shares in the last quarter. Vontobel Holding Ltd. lifted its holdings in shares of Sangamo Therapeutics by 412.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 241,440 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Sangamo Therapeutics in the second quarter worth about $67,000. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.